News
Dr. Reddy’s has benefitted significantly from gRevlimid sales in the US in the last three years. But that opportunity is now closing by FY26-end. The company has made significant investments ...
Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.
LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and further to 7.19% as of March 2025, according to the latest shareholding ...
Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda (pembrolizumab), for global markets.
CHENNAI: Shares of Dr Reddy’s Laboratories surged over 3% in early trade on Thursday after the Indian drug maker announced a global licensing agreement with Alvotech, an Iceland-based ...
On Thursday, HMWSSB MD Ashok Reddy visited the STP sites along with executive director Mayank Mittal to check the progress of the works.
Dr Reddy's Laboratories intensifies focus on Indian market with innovative drugs, collaborations, and digital therapeutics for growth.
Dr Satish Reddy takes charge as aerospace, defence advisor Speaking to the media, Dr Reddy expressed gratitude to the Chief Minister for the opportunity.
Pharma giant Dr Reddy’s Laboratories is reportedly cutting workforce-related costs by nearly 25%, signaling one of the most aggressive corporate restructurings in the Indian pharmaceutical ...
Dr Reddy Q4 results 2023 preview: The pharmaceutical company is likely to report a 13 per cent year-on-year (YoY) increase in its consolidated revenue to Rs 6,174 crore against Rs 5,475 crore logged ...
Dr Reddy's ramps up R&D investment with a focus on biosimilars, generics, and biologics, while expecting continued gains from Revlimid amid robust quarterly revenue growth.
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has expanded its global footprint by establishing a new wholly-owned subsidiary, Dr. Reddy’s Denmark ApS, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results